trending Market Intelligence /marketintelligence/en/news-insights/trending/JcWKEQr_rw7CLPjcYCDQAQ2 content esgSubNav
In This List

Cellectar Biosciences receives patent protection for cancer drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Cellectar Biosciences receives patent protection for cancer drug

Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.

The patent protection will last through the end of 2035.